We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Dyax and MorphoSys Sign License Agreement on Antibody-Related Patents

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dyax and MorphoSys Sign License Agreement on Antibody-Related Patents"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Dyax Corp. and MorphoSys AG have announced the signing of a licensing agreement covering a broad patent portfolio relating to antibodies and other proteins.

The agreement grants MorphoSys a fully paid-up license to a variety of phage display-related patents from Dyax as well as other patents, including several relating to methods for displaying and selecting antibodies and other proteins through the use of alternative types of display.

As part of the license agreement, MorphoSys gains the right to sublicense the patents in conjunction with its proprietary technology. The license agreement provides MorphoSys with flexibility for future technology development to further diversify its antibody technology portfolio and improve its offering for therapeutic, diagnostic and research customers. Financial terms were not disclosed.

Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, stated, “This agreement with MorphoSys recognizes the true value of our intellectual property portfolio as our powerful proprietary display technologies continue to be attractive to many companies in the biotechnology and pharmaceutical industry.”

Mr. Blair added, “We are pleased to have entered into this licensing agreement with MorphoSys.”

“We are very pleased about this agreement with Dyax, which provides us even greater flexibility for our future technology development plans,” commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.